Ebola Virus in 2026
The world is once again confronting Ebola — and this time, the threat carries characteristics that make it particularly difficult to manage. On May 17, 2026, the World Health Organization (WHO) Director-General officially declared a Public Health Emergency of International Concern (PHEIC) over an Ebola outbreak caused by the Bundibugyo virus in the Democratic Republic of the Congo (DRC) and Uganda — the most severe level of global health alarm under the International Health Regulations (2005). This declaration marks the 17th Ebola disease outbreak in DRC since the virus was first identified in 1976, and only the third documented outbreak in human history caused by the Bundibugyo strain — a species for which there are currently no approved vaccines or specific therapeutics. As of May 18, 2026, the outbreak has spread across 9 health zones in Ituri Province, with 10 confirmed cases, 336 suspected cases, and 88 suspected deaths in DRC, plus 2 confirmed cases including 1 death in Uganda among individuals who had traveled from DRC. The WHO has warned that the true scale of infections is likely significantly larger than what is currently being detected, citing a high positivity rate among early samples and a critical four-week gap between the onset of the first known case and laboratory confirmation of the outbreak.
The broader Ebola story in 2026 is one of accelerating frequency and evolving complexity. Prior to the current Bundibugyo outbreak, DRC had already endured its 16th Ebola outbreak — an Ebola Zaire virus (EBOV) outbreak declared on September 4, 2025, which ultimately caused 64 cases (53 confirmed, 11 probable) and 45 deaths before being declared over on December 1, 2025, with a case fatality rate of 70.3%. And before that, Uganda reported a confirmed case of Ebola Sudan virus on January 30, 2025, with the outbreak declared over on April 26, 2025. Three separate Ebola events across two countries within a single year. Ebola is no longer just an episodic African crisis — it is an accelerating, multi-strain, borderless viral threat that demands global understanding. This article brings together every verified statistic on Ebola virus strains in 2026 — drawn exclusively from WHO, CDC, peer-reviewed public health journals, and official government health authorities — alongside essential precaution and prevention facts every informed reader needs.
Interesting Facts: Ebola Strains Statistics 2026
EBOLA VIRUS STATISTICS 2026 — KEY FACTS AT A GLANCE
══════════════════════════════════════════════════════════════════════════
FACT 01 ░░░░░░░░░░░░░░░░ PHEIC declared May 17, 2026 — WHO (Bundibugyo)
FACT 02 ░░░░░░░░░░░░░░░ 17th outbreak in DRC since 1976 (active May 2026)
FACT 03 ░░░░░░░░░░░░░░ 336 suspected + 10 confirmed DRC cases (May 18, 2026)
FACT 04 ░░░░░░░░░░░░░ 88 suspected deaths in DRC as of May 18, 2026
FACT 05 ░░░░░░░░░░░░ 9 health zones affected in Ituri Province, DRC
FACT 06 ░░░░░░░░░░░ 2 confirmed cases (1 death) in Uganda — imported from DRC
FACT 07 ░░░░░░░░░░ 6 Ebola species; 4 infect humans; Zaire most deadly (up to 90% CFR)
FACT 08 ░░░░░░░░░ Bundibugyo CFR: 30–50% — NO vaccine, NO approved treatment
FACT 09 ░░░░░░░ 2014–2016 West Africa outbreak: 28,646 cases, 11,323 deaths
FACT 10 ░░░░░░ Incubation period: 2 to 21 days (virus undetectable/non-infectious)
FACT 11 ░░░░░ Overall historical Ebola CFR: ~50% (range 25%–90%)
FACT 12 ░░░░ 2018–2020 DRC outbreak: 3,470 cases, 2,287 deaths (2nd largest ever)
FACT 13 ░░░ 4 healthcare workers died in 4 days — May 2026 DRC outbreak
FACT 14 ░░ Bundibugyo only caused 2 outbreaks in 50 years — this is 3rd
FACT 15 ░ Sexual transmission confirmed up to 500 days post-infection
══════════════════════════════════════════════════════════════════════════
| Interesting Fact | Verified Statistic / Detail |
|---|---|
| PHEIC declared — May 17, 2026 | WHO Director-General declared the Ebola Bundibugyo outbreak in DRC and Uganda a Public Health Emergency of International Concern — its highest alert level under IHR (2005) |
| Current active outbreak scale (as of May 18, 2026) | DRC: 10 confirmed, 336 suspected cases, 88 suspected deaths across 9 health zones; Uganda: 2 confirmed cases, 1 death |
| DRC’s 17th outbreak since 1976 | The May 2026 Bundibugyo outbreak is the 17th Ebola disease outbreak in DRC since the virus was first identified in 1976 |
| Most recent prior DRC outbreak | September–December 2025: Ebola Zaire virus, Kasai Province — 64 cases (53 confirmed, 11 probable), 45 deaths; CFR: 70.3% |
| Uganda Sudan virus outbreak 2025 | January 30, 2025: Uganda confirmed Ebola Sudan virus; outbreak declared over April 26, 2025 |
| Only 3rd Bundibugyo outbreak in history | Bundibugyo virus had only caused two prior documented outbreaks (2007 in DRC; 2012 DRC/Uganda) in 50 years of surveillance |
| No vaccine, no treatment for Bundibugyo | Unlike Ebola-Zaire, there are no licensed vaccines or specific therapeutics for Bundibugyo virus disease; no late-stage candidates ready for deployment |
| Six Ebola species — four infect humans | The six orthoebolavirus species are: Zaire, Sudan, Bundibugyo, Taï Forest, Reston, and Bombali; only the first four have caused disease in humans |
| Zaire ebolavirus — highest lethality | Zaire has a crude CFR of ~79% untreated; overall Ebola CFR across all strains averages 50% (range: 25%–90% depending on strain and care setting) |
| 2014–2016 West Africa epidemic — worst ever | 28,646 total cases (confirmed, probable, suspected) and 11,323 deaths — the largest Ebola outbreak in recorded history; caused by Zaire ebolavirus |
| 2018–2020 DRC outbreak — second largest | 3,470 cases and 2,287 deaths in North Kivu and Ituri — caused by Zaire ebolavirus; a small number of cases also crossed into Uganda |
| Incubation period | 2 to 21 days — a person infected with Ebola cannot spread the disease until symptoms develop |
| Healthcare worker deaths — May 2026 | Four healthcare workers died within a four-day span at Mongbwalu General Referral Hospital, DRC — exposing critical gaps in infection prevention and control |
| Ebola first discovered in 1976 | Two simultaneous outbreaks occurred in what is now South Sudan and in DRC in 1976, near the Ebola River from which the disease takes its name |
| Sexual transmission window | The Ebola virus can persist in semen and has been confirmed to cause sexual transmission up to 500 days after initial infection — a documented risk in male survivors |
Source: World Health Organization — Disease Outbreak News: Bundibugyo Virus, DRC and Uganda (DON602, May 17, 2026); WHO PHEIC Declaration, May 17, 2026; CDC — Ebola Disease: Current Situation (Updated May 18, 2026); CDC — Ebola Outbreak History (Updated December 2025); CDC — Ebola Disease Basics; Imperial College London Ebola 2026 Expert Q&A (May 2026); LSHTM Rapid Reaction: Ebola Outbreak in DRC and Uganda (May 2026)
Reading those facts in sequence tells a story that demands serious attention. Three Ebola events in two countries in under eighteen months. A declared global health emergency. A viral strain for which no medical countermeasure — no vaccine, no therapeutic — has been approved. And an outbreak unfolding in one of the most conflict-affected, infrastructurally limited, and densely mobile regions on earth. The four-week detection gap between the first known case (symptom onset: April 24, 2026) and laboratory confirmation (May 14–15, 2026) is perhaps the single most alarming operational detail in the May 2026 outbreak — it suggests that Ebola-compatible symptoms were circulating in communities for nearly a month before the world knew. During that window, four healthcare workers died, community funerals may have spread infection further, and the virus migrated from Mongbwalu to Rwampara, Bunia, and eventually to Kampala. The WHO’s candid assessment that the true outbreak scale is “potentially much larger than what is currently being detected” is not alarmism — it is an honest reading of a situation defined by surveillance gaps.
The historical facts around Ebola case fatality rates deserve equal emphasis. The 2025 DRC Kasai outbreak had a CFR of 70.3% — which means roughly seven in ten people who contracted confirmed or probable Ebola in that outbreak died from it. The current Bundibugyo strain, while less acutely lethal than Zaire (with historical CFRs of 30%–50%), is still a disease that kills a significant proportion of those it infects, in contexts where supportive care — the primary tool for improving survival — is chronically underfunded and physically difficult to deliver. The 15-fact profile above is not background context; it is the active, real-time face of a disease that killed over 11,000 people in West Africa just a decade ago and is once again testing the boundaries of international containment.
Ebola Virus Strains Comparison Statistics 2026 | Six Species Data
EBOLA STRAINS — CASE FATALITY RATE AND HUMAN DISEASE PROFILE (WHO/CDC, 2026)
═══════════════════════════════════════════════════════════════════════════════
Zaire ████████████████████████████████████████ CFR: 25–90% (avg ~79%)
Sudan ████████████████████████████ CFR: ~50% (range 41–65%)
Bundibugyo ████████████████ CFR: 30–50%
Taï Forest ░░░░░░░░░░ (1 case ever, survived) CFR: N/A (1 human case)
Reston ░░░░ (primates only — no human disease) CFR: N/A for humans
Bombali ░░░░ (bats only — no human cases yet) CFR: N/A for humans
═══════════════════════════════════════════════════════════════════════════════
OUTBREAKS CAUSED (human, as of 2026):
Zaire: 40+ outbreaks since 1976 — most common and deadliest
Sudan: 9 outbreaks since 1976
Bundibugyo: 3 outbreaks (2007, 2012, 2026) ← 3rd outbreak active NOW
Taï Forest: 1 outbreak (1994, Côte d'Ivoire — single case)
═══════════════════════════════════════════════════════════════════════════════
| Strain (Species) | Scientific Name | CFR (Untreated) | Human Outbreaks | Vaccine Available? | Approved Treatment? |
|---|---|---|---|---|---|
| Zaire (EBOV) | Orthoebolavirus zairense | 25%–90% (avg ~79%) | 40+ since 1976 | Yes — ERVEBO® (FDA-approved) | Yes — Inmazeb, Ebanga (FDA-approved) |
| Sudan (SUDV) | Orthoebolavirus sudanense | ~50% (range 41–65%) | 9 outbreaks | No licensed vaccine | No specific treatment |
| Bundibugyo (BDBV) | Orthoebolavirus bundibugyoense | 30%–50% | 3 (2007, 2012, 2026) | No licensed vaccine | No approved treatment |
| Taï Forest (TAFV) | Orthoebolavirus taiense | Not established | 1 (1994, Côte d’Ivoire) | No | No |
| Reston (RESTV) | Orthoebolavirus restonense | None in humans | 0 human disease cases | No | No |
| Bombali (BOMV) | Orthoebolavirus bombaliense | None in humans | 0 human cases identified | No | No |
Source: CDC — Ebola Disease Basics (Updated May 2026); WHO — Ebola Disease Fact Sheet (April 2025); Imperial College London — Ebola 2026 Expert Q&A (May 2026); NIH/PMC — Emergent Risk Group-4 Filoviruses (2023); CDC — Outbreak History (December 2025)
Understanding the six Ebola species is foundational to making sense of why the current 2026 outbreak demands a different response than previous ones. The most extensively documented species — Zaire ebolavirus — is responsible for the majority of all recorded Ebola outbreaks, including the devastating 2014–2016 West Africa epidemic and the 2018–2020 DRC epidemic. It is also the only strain for which the world has approved medical countermeasures: the ERVEBO® vaccine (rVSV-ZEBOV, FDA-approved in 2019) and two monoclonal antibody treatments — Inmazeb and Ebanga (both FDA-approved in 2020–2021). The availability of these tools has fundamentally changed the Zaire outbreak response toolkit — even with a CFR that can theoretically reach 90% without care, rapid deployment of ERVEBO through ring vaccination strategies has demonstrably reduced transmission in post-2019 outbreaks. Sudan ebolavirus — responsible for nine outbreaks since 1976, most recently in Uganda in January 2025 — sits in a dangerous middle ground: well-characterised enough to be tracked but without an approved vaccine or specific therapeutic. Several Sudan virus vaccine candidates have been in clinical trials, but none has reached licensure.
Bundibugyo ebolavirus is the least understood and most medically undefended of the three clinically significant species. Discovered only in 2007 during an outbreak in Uganda’s Bundibugyo district, it has caused just three documented human outbreaks in history — with the current May 2026 DRC/Uganda event being the third. Its CFR of 30%–50% is lower than Zaire’s worst-case figures, but the complete absence of vaccines or approved therapeutics means that every Bundibugyo response must rely entirely on classical outbreak control: case isolation, contact tracing, infection prevention and control, safe burials, and supportive care. Reston ebolavirus and Bombali ebolavirus — the two species that have never caused confirmed human disease — serve as important reminders that the orthoebolavirus genus is broader and more diverse than its two most lethal members. Reston has been found in non-human primates and pigs in the Philippines and the United States; Bombali was identified in bats in Sierra Leone in 2018. Neither has jumped to humans yet — but both are monitored as potential future spillover risks.
Ebola Outbreak History Statistics 2026 | Major Outbreaks 1976–2026
MAJOR EBOLA OUTBREAKS — CASES AND DEATHS (1976–2026)
══════════════════════════════════════════════════════════════════════════════════
1976 (DRC, Zaire) ████ 318 cases, 280 deaths CFR 88%
1995 (DRC, Zaire) ████████ 315 cases, 254 deaths CFR 81%
2000 (Uganda, Sudan) ████████████ 425 cases, 224 deaths CFR 53%
2007 (DRC, BDBV) ████████████████ 264 cases, 187 deaths CFR 71%
2012 (DRC, BDBV) ████ 57 cases, 29 deaths CFR 51%
2014–16 (W.Africa) ████████████████████████ 28,646 cases 11,323 deaths CFR 40%
2018–20 (DRC, Zaire) ████████████████████ 3,470 cases 2,287 deaths CFR 66%
2022 (Uganda, Sudan) ████████████ 164 cases, 55 deaths CFR 34%
Sep–Dec 2025 (DRC) ███ 64 cases, 45 deaths CFR 70%
Jan–Apr 2025 (Uganda) ██ (1 confirmed; outbreak ended Apr 2025)
May 2026 (DRC/Uganda) ██████████████ (ACTIVE) 10 conf / 336 susp / 88 deaths
══════════════════════════════════════════════════════════════════════════════════
| Year | Country / Region | Strain | Total Cases | Deaths | CFR |
|---|---|---|---|---|---|
| 1976 | DRC (then Zaire) | Zaire (EBOV) | 318 | 280 | 88% |
| 1995 | DRC (Kikwit) | Zaire (EBOV) | 315 | 254 | 81% |
| 2000–2001 | Uganda | Sudan (SUDV) | 425 | 224 | 53% |
| 2007–2008 | DRC (Bundibugyo) | Bundibugyo (BDBV) | 264 | 187 | 71% |
| 2012 | DRC | Bundibugyo (BDBV) | 57 | 29 | 51% |
| 2014–2016 | Guinea, Liberia, Sierra Leone | Zaire (EBOV) | 28,646 | 11,323 | 40% |
| 2018–2020 | DRC (North Kivu / Ituri) | Zaire (EBOV) | 3,470 | 2,287 | 66% |
| 2022 | Uganda | Sudan (SUDV) | 164 (142 conf. + 22 prob.) | 55 | 34% |
| Sep–Dec 2025 | DRC (Kasai Province) | Zaire (EBOV) | 64 (53 conf, 11 prob.) | 45 | 70.3% |
| Jan–Apr 2025 | Uganda | Sudan (SUDV) | 1 confirmed | 1 | — |
| May 2026 (active) | DRC (Ituri) + Uganda | Bundibugyo (BDBV) | 10 confirmed + 336 suspected | 88 suspected + 1 confirmed | Ongoing |
Source: WHO — Disease Outbreak News: Bundibugyo Virus DRC and Uganda (DON602, May 17, 2026); CDC — Ebola Outbreak History (Updated December 2025); WHO — End of Outbreak Declaration, DRC, December 1, 2025; WHO PHEIC Declaration May 17, 2026; CDC — Ebola Disease Current Situation (Updated May 18, 2026)
The outbreak history table reveals a disease that has never been truly contained for long — it disappears between outbreaks but re-emerges with alarming regularity from its still-unknown animal reservoir. The 1976 Zaire outbreak had the highest CFR of any documented Ebola event at 88% — seven out of every eight infected people died. The 2000–2001 Uganda outbreak (Sudan strain, 425 cases) was, at the time, the largest Ebola outbreak on record — a distinction held until the 2014–2016 West Africa epidemic shattered all previous scales with 28,646 cases and 11,323 deaths across three countries, spread over more than two years, and accompanied by the export of individual cases to the United States, Spain, the United Kingdom, and Italy. The West Africa epidemic was the watershed moment that catalysed the development of the ERVEBO® vaccine and the Inmazeb and Ebanga treatments — investments that have meaningfully changed the Zaire ebolavirus response. But they have done nothing for Sudan and Bundibugyo — the strains responsible for every major outbreak since 2022.
The year 2025 was the busiest single year for Ebola since 2019. DRC experienced its 16th outbreak (Zaire, Kasai Province: 64 cases, 45 deaths, CFR 70.3%), and Uganda experienced a Sudan strain event. The September–December 2025 DRC outbreak is particularly instructive: it had a CFR of 70.3% — among the highest of any recent outbreak and reflective of how lethal Ebola Zaire remains even in settings where some treatment capacity exists. The epicentres in Dikolo (26 cases, 15 deaths) and Bulape (24 cases, 22 deaths) together accounted for 78.1% of all cases and 82.2% of all deaths — a geographic concentration that speaks to how community-level transmission dynamics can dominate early outbreak trajectories before containment infrastructure arrives. The May 2026 outbreak now adds a third Bundibugyo event to the history books — and its position as the largest Bundibugyo outbreak ever recorded makes it genuinely unprecedented in terms of the epidemiology of that specific strain.
Ebola Transmission and Biological Statistics 2026 | Virus Biology Data
EBOLA VIRUS TRANSMISSION — KEY BIOLOGICAL FACTS (WHO/CDC, 2026)
═══════════════════════════════════════════════════════════════════════════
INCUBATION PERIOD: 2 to 21 days (average ~8–12 days)
INFECTIOUS WINDOW: From symptom onset onward (NOT during incubation)
PRIMARY TRANSMISSION ROUTES:
Direct contact with infected bodily fluids ████████████████████ HIGH
Mucous membranes (eyes, nose, mouth) █████████████████ HIGH
Contaminated surfaces / fomites ████████████ MODERATE
Unsafe burial practices █████████████████ HIGH
Healthcare-associated infection █████████████████ HIGH
Sexual transmission (survivors) █████████ PRESENT (up to 500 days)
Airborne / droplet / respiratory route ░░░░░ NOT DOCUMENTED
NATURAL RESERVOIR: Fruit bats (suspected; not conclusively proven)
SPILLOVER: Zoonotic — from bats / primates to humans
GENOME: Negative-strand RNA, ~19 kb, 7 genes
═══════════════════════════════════════════════════════════════════════════
| Biological / Transmission Factor | Detail | Source |
|---|---|---|
| Incubation period | 2 to 21 days; average ~8–12 days | WHO Ebola Fact Sheet (2025) |
| Infectious before symptoms? | No — person cannot spread disease during incubation | CDC / WHO |
| Primary transmission — human to human | Direct contact with blood, secretions, organs, bodily fluids of infected person | WHO |
| Contaminated surfaces / materials | Bedding, clothing, medical equipment — indirect contact route | WHO |
| Healthcare-associated transmission | Significant risk where IPC (Infection Prevention and Control) protocols are insufficient | WHO DON602 (May 2026) |
| Unsafe burial practices | Direct contact with bodies of deceased patients — a major driver of community spread | WHO / CDC |
| Sexual transmission | Confirmed in male survivors up to 500 days post-infection via semen persistence | NIH/PMC (2023) |
| Airborne / respiratory transmission | Not documented — Ebola does not spread through casual contact or air | CDC (May 2026) |
| Natural reservoir (suspected) | Fruit bats (Pteropodidae family) — strong but not conclusively proven | WHO |
| Other animal sources | Non-human primates (chimpanzees, gorillas), porcupines | WHO |
| Genome structure | Negative-strand RNA virus, approximately 19,000 nucleotides, 7 genes | NIH/PMC Filovirus Review (2023) |
| Key diagnostic methods | Reverse-transcriptase PCR (RT-PCR), antibody-capture ELISA, virus isolation | WHO / CDC |
Source: WHO — Ebola Disease Fact Sheet (Updated April 2025); CDC — Ebola Disease Basics (May 2026); WHO EMRO — Ebola Overview; NIH/PMC — Emergent Risk Group-4 Filoviruses: A Paradox in Progress (2023); WHO — DON602 Bundibugyo Outbreak (May 17, 2026)
The transmission biology of Ebola is the foundation of every prevention and response strategy — and the most important single fact for the general public to understand is one that is frequently misunderstood: Ebola does not spread through the air. It is not transmitted through casual contact — sitting near an infected person, breathing the same air, shaking hands with someone who is not yet showing symptoms. Ebola requires direct contact with the bodily fluids of a person who is actively sick: blood, saliva, sweat, vomit, urine, feces, semen, or breast milk. This means that the disease, while extraordinarily lethal once it takes hold, is also theoretically containable through rigorous infection prevention and control if applied consistently and early. The 4 healthcare worker deaths in four days at Mongbwalu General Referral Hospital in May 2026 are a vivid demonstration of what happens when those controls fail — four trained medical professionals dead in the space of a working week, each one a consequence of a breach in protective protocols that proper PPE, training, and supplies could have prevented.
The suspected natural reservoir of Ebola virus — most likely fruit bats of the Pteropodidae family — has never been conclusively confirmed through isolation of live virus, even though decades of serological and genetic evidence point strongly in that direction. The mechanism by which the virus periodically “spills over” from its animal reservoir into human populations is still not fully understood. What is known is that initial human infection typically occurs through handling of infected wild animals — butchering bushmeat, hunting, or incidental contact — and that once a single human is infected, the disease then spreads through human-to-human transmission via bodily fluids. The high positivity rate of early samples in the May 2026 DRC outbreak (8 of 13 samples tested positive) suggests that by the time the alert was raised, the virus was already widely distributed across the community — a direct consequence of the four-week gap between first human symptoms and outbreak confirmation. That gap, in a disease with an incubation period of up to 21 days and a transmission window from symptom onset, represents an enormous and unquantifiable window of community exposure.
Ebola Symptoms and Clinical Statistics 2026 | Disease Progression Data
EBOLA DISEASE PROGRESSION — CLINICAL TIMELINE (WHO/CDC 2026)
═══════════════════════════════════════════════════════════════════════════
PHASE 1 — DRY PHASE (Days 1–4 of illness):
Fever ████████████████████████████████████ 73–100% of cases
Fatigue █████████████████████████████ common
Muscle/joint pain ████████████████████████ common
Headache █████████████████████████ common
Sore throat ██████████████████ common
PHASE 2 — WET PHASE (Days 4–10 of illness):
Vomiting ████████████████████████████████ 73% of cases
Diarrhea ████████████████████████████████ 73% of cases
Abdominal pain ██████████████████████████████ 60% of cases
Rash ████████████████████████ common
Conjunctivitis ████████████ 33% of cases
Internal/external bleeding ████████████████ in some cases
TYPICAL DURATION (Bundibugyo 2007 cohort):
Onset to death: median 9 days
Onset to discharge: median 10 days
═══════════════════════════════════════════════════════════════════════════
| Symptom / Clinical Sign | Prevalence Among Cases | Phase of Illness | Source |
|---|---|---|---|
| Sudden fever | 73–100% of cases | Early (Days 1–4) | WHO; NIH/PMC |
| Fatigue / weakness | Very common | Early (Days 1–4) | WHO; CDC |
| Muscle and joint pain | Very common | Early (Days 1–4) | WHO; CDC |
| Headache | Very common | Early (Days 1–4) | WHO; CDC |
| Sore throat | Common | Early (Days 1–4) | WHO |
| Vomiting | ~73% of cases (Bundibugyo 2007 cohort) | Late (Days 4+) | NIH/PMC |
| Diarrhea | ~73% of cases | Late (Days 4+) | NIH/PMC |
| Abdominal pain | ~60% of cases | Late (Days 4+) | NIH/PMC |
| Rash | Common | Late (Days 4+) | WHO |
| Conjunctivitis (red eyes) | ~33% of cases | Late | NIH/PMC (Bundibugyo 2007) |
| Internal / external bleeding | Present in some cases | Late (severe phase) | WHO; CDC |
| Impaired kidney and liver function | Present as disease progresses | Late | WHO |
| Onset to death (median, Bundibugyo) | 9 days | — | NIH/PMC (2007 outbreak cohort) |
| Onset to discharge (survivors, median) | 10 days | — | NIH/PMC (2007 outbreak cohort) |
Source: WHO — Ebola Disease Fact Sheet (April 2025); CDC — Ebola Disease Basics (May 2026); NIH/PMC — Ebola Virus Disease Review (PMC4173971); WHO EMRO — Ebola Overview; WHO — DON602 (May 2026)
The clinical trajectory of Ebola disease follows a recognisable but rapidly escalating pattern that makes early identification both critical and extremely challenging. The disease’s early phase — often described as the “dry phase” — presents with symptoms that are clinically indistinguishable from malaria, typhoid fever, meningitis, influenza, and a host of other febrile illnesses common across sub-Saharan Africa. Fever, fatigue, headache, muscle pain, and sore throat are not specific to Ebola — they are the presenting symptoms of dozens of endemic conditions, which is precisely why healthcare workers in Ituri Province in April–May 2026 failed to raise the Ebola alarm for nearly four weeks. WHO explicitly acknowledged that the presence of “co-circulating arboviruses and influenza-like illnesses” masked the initial clinical suspicion for Ebola disease and contributed to community transmission. It is only when the disease progresses to its “wet phase” — with the onset of profuse vomiting, severe diarrhea, abdominal pain, rash, and in some cases haemorrhage — that the clinical picture becomes more suggestive of a viral haemorrhagic fever. By that point, however, the infected person has often already exposed family members, healthcare workers, and community members to their infectious bodily fluids.
The Bundibugyo-specific clinical data from the 2007 outbreak cohort — documented in a detailed prospective study of 26 hospitalised patients — provides the most granular available picture of this strain’s clinical course. Fever (73%), nausea/vomiting (73%), and diarrhea (73%) were the most commonly self-reported symptoms, followed by abdominal pain (60%) and conjunctivitis (33%). The median time from symptom onset to death was just 9 days — and for survivors, the median time to discharge was 10 days. This near-identical timeline for survivors and non-survivors underscores how fine the margin between survival and death can be, and how central early supportive care — intravenous rehydration, electrolyte replacement, maintenance of blood pressure, and treatment of secondary infections — is to improving outcomes. Post-Ebola syndrome is an additional and frequently overlooked dimension: survivors of all Ebola strains can experience uveitis (eye inflammation), arthralgia, fatigue, and neurological symptoms for months to years after recovery, and Ebola RNA has been detected in the aqueous humour of survivor eyes long after apparent recovery — a clinical reality that adds complexity to survivor care programs.
Ebola Precautions and Prevention Statistics 2026 | Key Protection Facts
EBOLA PREVENTION — WHO/CDC RECOMMENDED PRECAUTIONS (2026)
═══════════════════════════════════════════════════════════════════════════
LEVEL OF PROTECTION (when correctly applied):
PERSONAL PROTECTIVE EQUIPMENT (PPE — full): ████████████████████ HIGH
Ring vaccination (ERVEBO® — Zaire only): ████████████████████ HIGH
Contact tracing + isolation: ████████████████████ HIGH
Safe burial practices: ████████████████████ HIGH
Hand hygiene: █████████████████ EFFECTIVE
Avoiding bushmeat handling (spillover prev.): █████████████ IMPORTANT
Travel screening (symptomatic): █████████████ EFFECTIVE
BUNDIBUGYO-SPECIFIC LIMITATIONS:
No vaccine: ░░░░░░░░░░░░░░░░░░░░ ZERO protection
No licensed therapeutic: ░░░░░░░░░░░░░░░░░░░░ Supportive care only
No RCT-proven monoclonal Ab (BDBV): ░░░░░░░░░░░░░░░░░░░░ Under investigation
═══════════════════════════════════════════════════════════════════════════
| Precaution / Prevention Measure | Applies To | Effectiveness / Status | Source |
|---|---|---|---|
| Avoid direct contact with blood/bodily fluids of sick persons | General public / all settings | Primary prevention | WHO; CDC |
| Full PPE for healthcare workers | Clinical / outbreak settings | Critical; 4 HCW deaths in May 2026 from IPC failures | WHO DON602 (2026) |
| ERVEBO® ring vaccination | Zaire strain outbreaks only | Highly effective; no equivalent for Sudan or Bundibugyo | CDC / FDA |
| Contact tracing and quarantine | All outbreaks | Core containment tool; limits spread exponentially | WHO |
| Safe and dignified burials | Outbreak-affected communities | Eliminates a major transmission route | WHO |
| Isolation of confirmed/suspected cases | All healthcare settings | Prevents nosocomial spread | WHO; CDC |
| Hand hygiene — soap/water or alcohol sanitiser | All settings | Reduces fomite transmission | WHO |
| Avoid bushmeat and raw animal handling | Endemic areas | Reduces zoonotic spillover risk | WHO |
| Travel health notices and screening | International travelers to DRC/Uganda | CDC Level 1 Notice — Practice Usual Precautions (May 2026) | CDC (May 18, 2026) |
| Early supportive care | Confirmed / suspected cases | Most effective intervention currently for Bundibugyo | WHO; LSHTM (2026) |
| Survivor sexual precautions | Male Ebola survivors | Use condoms; avoid unprotected sex for at minimum 12 months post-recovery | WHO |
| Avoid handling bodies of deceased | Outbreak communities | Major transmission risk — defer to trained burial teams | WHO |
Source: WHO — Advice to Countries: Bundibugyo Virus Disease (DON602, May 17, 2026); CDC — Ebola Disease: Current Situation (May 18, 2026); CDC — Ebola Disease Basics; WHO EMRO — Ebola Disease Prevention; LSHTM — Rapid Reaction Ebola Outbreak (May 2026); WHO — Ebola Fact Sheet (April 2025)
The precaution framework for Ebola in 2026 is both clearer and more constrained than at any previous point in the disease’s recorded history. It is clearer because fifty years of outbreak response has produced a well-validated set of measures that work — isolation, contact tracing, safe burials, hand hygiene, PPE, and ring vaccination — that together constitute a proven playbook for containing Zaire ebolavirus outbreaks. It is more constrained because the two most active strains in 2025 and 2026 — Sudan and Bundibugyo — cannot be addressed by the vaccine or treatments developed for Zaire. ERVEBO®, the only FDA-approved Ebola vaccine, confers no protection against Sudan or Bundibugyo virus because it is based on the Zaire strain’s glycoprotein. The same applies to Inmazeb and Ebanga — the approved Zaire-specific monoclonal antibodies that dramatically improved survival odds in the 2018–2020 DRC outbreak. When healthcare workers in Mongbwalu, Ituri Province, faced the Bundibugyo virus in April and May 2026, there was no vaccine to offer them, no proven drug to prescribe, and no prophylactic protocol beyond strict PPE adherence. Four of them did not survive.
The most actionable prevention messages for the general public remain straightforward and highly effective: do not handle or consume raw bushmeat in endemic regions; avoid direct contact with the blood or bodily fluids of anyone suspected to be ill; observe strict hand hygiene; report fever and haemorrhagic symptoms immediately to healthcare providers if you have recently traveled to or from an active outbreak zone; and if traveling to DRC or Uganda, follow the CDC’s current travel health guidance (Level 1 Notice as of May 18, 2026). For healthcare workers in outbreak zones, the message is equally clear but operationally more demanding: full PPE — impermeable gown, gloves, eye protection, and N95 or equivalent respirator — must be donned correctly and completely for every interaction with a suspected or confirmed case. The four healthcare worker deaths in the May 2026 DRC outbreak are a direct reminder of what the absence of that protection means. WHO’s current outbreak response framework for the Bundibugyo event — deploying rapid response teams, establishing safe treatment centres, strengthening surveillance and laboratory capacity, and launching community engagement — represents the full arsenal available in the absence of a vaccine. It is a formidable public health toolkit. It is also, as the still-rising suspected case count makes clear, a toolkit that is being tested to its limits in real time.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
